Stock Analysis on Net

AbbVie Inc. (NYSE:ABBV)

$24.99

Analysis of Profitability Ratios
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Profitability Ratios (Summary)

AbbVie Inc., profitability ratios (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Return on Sales
Gross profit margin
Operating profit margin
Net profit margin
Return on Investment
Return on equity (ROE)
Return on assets (ROA)

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The profitability metrics exhibited considerable fluctuation throughout the observed period, spanning from March 2022 to December 2025. Initial values generally demonstrated strength, followed by a period of decline, and then a degree of recovery towards the end of the timeframe. A notable divergence in trends is apparent across the different profitability measures.

Gross Profit Margin
The gross profit margin began at 69.53% in March 2022 and showed initial stability before declining steadily to a low of 62.28% in March 2024. A subsequent recovery was observed, peaking at 70.93% in June 2025, before settling at 70.24% in December 2025. This suggests potential shifts in cost of goods sold or pricing strategies impacting the company’s production efficiency.
Operating Profit Margin
The operating profit margin followed a more pronounced downward trajectory. Starting at 32.68% in March 2022, it decreased to 23.50% in March 2024, reaching a low of 16.22% in December 2024. A significant rebound occurred in December 2025, with the margin increasing to 24.65%. This indicates that operating expenses, relative to revenue, have increased and then were subsequently managed more effectively.
Net Profit Margin
The net profit margin mirrored the trend of the operating profit margin, experiencing a substantial decline from 22.00% in March 2022 to a low of 6.91% in December 2025. Prior to this, the margin fluctuated, reaching a peak of 23.19% in September 2022, before falling to 8.95% in December 2023. This suggests that factors beyond operating performance, such as interest expenses or taxes, also contributed to the overall profitability decline.
Return on Equity (ROE)
Return on equity demonstrated significant volatility. It began at a high of 76.64% in March 2022, decreased to 57.14% in March 2023, and then experienced a dramatic increase to 295.42% in March 2025. The subsequent values for June and September 2025 are unavailable. This substantial fluctuation suggests considerable changes in net income and/or shareholder equity.
Return on Assets (ROA)
Return on assets exhibited a consistent downward trend from 8.71% in March 2022 to a low of 1.78% in September 2025. A slight recovery to 3.15% was observed in December 2025. This indicates a decreasing ability to generate profit from the company’s assets, potentially due to inefficient asset utilization or declining profitability.

In summary, the observed period was characterized by a general decline in profitability, particularly in operating and net profit margins, followed by a partial recovery in the final quarters. The dramatic fluctuation in ROE warrants further investigation, while the consistent decline in ROA suggests a need to improve asset efficiency. The gross profit margin demonstrated more resilience, indicating that core production profitability remained relatively stable despite broader challenges.


Return on Sales


Return on Investment


Gross Profit Margin

AbbVie Inc., gross profit margin calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Gross margin
Net revenues
Profitability Ratio
Gross profit margin1
Benchmarks
Gross Profit Margin, Competitors2
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q4 2025 Calculation
Gross profit margin = 100 × (Gross marginQ4 2025 + Gross marginQ3 2025 + Gross marginQ2 2025 + Gross marginQ1 2025) ÷ (Net revenuesQ4 2025 + Net revenuesQ3 2025 + Net revenuesQ2 2025 + Net revenuesQ1 2025)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


The gross profit margin exhibited fluctuations over the observed period, spanning from March 31, 2022, to December 31, 2025. Initially, the margin demonstrated relative stability, followed by a noticeable decline and subsequent recovery.

Initial Stability (Mar 31, 2022 – Dec 31, 2022)
From March 31, 2022, through December 31, 2022, the gross profit margin remained consistently high, fluctuating between 69.53% and 70.48%. This period indicates a stable cost structure relative to revenue generation.
Decline (Mar 31, 2023 – Dec 31, 2023)
A downward trend commenced in March 31, 2023, with the gross profit margin decreasing from 69.43% to a low of 62.42% by December 31, 2023. This decline suggests increasing costs of goods sold relative to net revenues, or potentially pricing pressures.
Recovery and Stabilization (Mar 31, 2024 – Jun 30, 2025)
Beginning March 31, 2024, the gross profit margin began to recover, reaching 67.21% and peaking at 70.93% by June 30, 2025. This recovery indicates successful cost management strategies or improved pricing power. The margin concluded the period at 70.24%, demonstrating a return towards levels observed in the earlier part of the analyzed timeframe.

The largest single-quarter decrease occurred between September 30, 2023, and December 31, 2023, with a drop of 3.34 percentage points. Conversely, the most significant single-quarter increase was observed between March 31, 2025, and June 30, 2025, with an increase of 3.9 percentage points. These fluctuations warrant further investigation into the underlying cost and revenue drivers during those specific periods.

Net Revenues Correlation
While not the primary focus, net revenues generally increased over the period, except for a decrease observed in the first quarter of 2023. The fluctuations in gross profit margin do not appear directly correlated with changes in net revenues, suggesting that cost of goods sold is a more significant driver of the observed margin changes.

Overall, the gross profit margin demonstrates a cyclical pattern of stability, decline, and recovery. The recent upward trend is encouraging, but continued monitoring is recommended to ensure sustained profitability.


Operating Profit Margin

AbbVie Inc., operating profit margin calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Operating earnings
Net revenues
Profitability Ratio
Operating profit margin1
Benchmarks
Operating Profit Margin, Competitors2
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q4 2025 Calculation
Operating profit margin = 100 × (Operating earningsQ4 2025 + Operating earningsQ3 2025 + Operating earningsQ2 2025 + Operating earningsQ1 2025) ÷ (Net revenuesQ4 2025 + Net revenuesQ3 2025 + Net revenuesQ2 2025 + Net revenuesQ1 2025)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


The operating profit margin exhibited fluctuations over the observed period, spanning from March 31, 2022, to December 31, 2025. Initial values demonstrated a relatively stable performance, followed by a period of decline and subsequent recovery.

Initial Stability and Subsequent Decline (Q1 2022 - Q4 2023)
From March 31, 2022, to December 31, 2022, the operating profit margin remained within a narrow range, fluctuating between 30.33% and 32.68%. A gradual downward trend commenced in the first half of 2023, with the margin decreasing from 28.49% in March to 27.32% in September. This decline continued into the fourth quarter of 2023, reaching a low of 23.49%.
Bottoming Out and Initial Recovery (Q1 2024 - Q2 2024)
The operating profit margin stabilized somewhat in the first half of 2024, registering at 23.50% and 22.31% respectively. While still representing a lower level compared to the earlier periods, this suggests a potential bottoming out of the declining trend.
Significant Volatility and Recovery (Q3 2024 - Q4 2025)
A notable decrease occurred in the third quarter of 2024, with the operating profit margin falling to 16.22%. This was followed by a recovery in the fourth quarter of 2024, reaching 17.56%. The first half of 2025 showed further improvement, with the margin increasing to 18.80% in June. A subsequent decline to 15.16% was observed in September 2025, before a substantial recovery to 24.65% by December 31, 2025. This final quarter represents the highest margin observed since the second quarter of 2022.

Overall, the operating profit margin demonstrated considerable volatility throughout the analyzed timeframe. While a general downward trend was evident from early 2023 through the third quarter of 2024, the final quarters of 2024 and 2025 indicate a potential shift towards improved profitability, culminating in a strong finish to the period.


Net Profit Margin

AbbVie Inc., net profit margin calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Net earnings attributable to AbbVie Inc.
Net revenues
Profitability Ratio
Net profit margin1
Benchmarks
Net Profit Margin, Competitors2
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q4 2025 Calculation
Net profit margin = 100 × (Net earnings attributable to AbbVie Inc.Q4 2025 + Net earnings attributable to AbbVie Inc.Q3 2025 + Net earnings attributable to AbbVie Inc.Q2 2025 + Net earnings attributable to AbbVie Inc.Q1 2025) ÷ (Net revenuesQ4 2025 + Net revenuesQ3 2025 + Net revenuesQ2 2025 + Net revenuesQ1 2025)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


The net profit margin exhibited considerable fluctuation throughout the observed period, spanning from March 31, 2022, to December 31, 2025. Initial values demonstrated a strong profitability position, followed by a marked decline and subsequent stabilization with continued variability.

Initial Period (Mar 31, 2022 – Dec 31, 2022)
The net profit margin began at 22.00% in March 2022 and remained consistently high, peaking at 23.19% in September 2022. A slight decrease was noted in December 2022, settling at 20.39%, but remained within a robust range.
Significant Decline (Mar 31, 2023 – Dec 31, 2023)
A substantial reduction in net profit margin commenced in March 2023, falling to 13.37%. This downward trend continued through the remainder of the year, reaching a low of 8.95% in December 2023. This period reflects a significant erosion of profitability relative to the prior year.
Stabilization and Continued Variability (Mar 31, 2024 – Dec 31, 2025)
Following the decline, the net profit margin showed some stabilization, fluctuating between approximately 7.31% and 11.02% from March 2024 through September 2025. However, it did not return to the levels observed in 2022. A slight increase to 6.91% was recorded in December 2025, but remained considerably lower than initial values. Notably, a negative value of -7.59% was recorded in September 2024, indicating a net loss for that quarter.

Overall, the trend indicates a shift from a highly profitable position to a more volatile and lower-margin environment. While some recovery is observed towards the end of the period, the net profit margin remains significantly below its earlier levels. The negative margin in September 2024 warrants further investigation.


Return on Equity (ROE)

AbbVie Inc., ROE calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Net earnings attributable to AbbVie Inc.
Stockholders’ equity (deficit)
Profitability Ratio
ROE1
Benchmarks
ROE, Competitors2
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q4 2025 Calculation
ROE = 100 × (Net earnings attributable to AbbVie Inc.Q4 2025 + Net earnings attributable to AbbVie Inc.Q3 2025 + Net earnings attributable to AbbVie Inc.Q2 2025 + Net earnings attributable to AbbVie Inc.Q1 2025) ÷ Stockholders’ equity (deficit)
= 100 × ( + + + ) ÷ =

2 Click competitor name to see calculations.


The Return on Equity (ROE) exhibited considerable fluctuation over the observed period, spanning from March 31, 2022, to December 31, 2025. Initial values were exceptionally high, followed by a period of decline and subsequent volatility, culminating in unusually elevated figures towards the end of the analyzed timeframe.

Initial High Performance (Mar 31, 2022 – Jun 30, 2022)
ROE began at 76.64% in March 2022 and peaked at 86.24% in June 2022. This indicates a strong return generated on shareholders’ equity during this initial period. The values suggest efficient utilization of equity financing to generate profits.
Subsequent Decline (Sep 30, 2022 – Dec 31, 2023)
From September 2022 through December 2023, a downward trend in ROE was observed. The ratio decreased from 83.83% to 46.94%. This decline coincided with a reduction in net earnings and, more significantly, a substantial decrease in stockholders’ equity. The decreasing equity base amplified the impact of lower earnings on the ROE calculation.
Volatility and Rebound (Mar 31, 2024 – Dec 31, 2024)
The first half of 2024 showed a recovery, with ROE increasing from 74.85% in March to 78.77% in June and further to 84.91% in September. This improvement was likely driven by a stabilization in net earnings. However, a significant outlier occurred in December 2024, with ROE reaching 128.66%, likely due to a substantial decrease in stockholders’ equity (moving into deficit territory).
Extreme Fluctuations and Negative Equity (Mar 31, 2025 – Dec 31, 2025)
The final period demonstrated extreme volatility. ROE surged to 295.42% in March 2025, coinciding with a dramatic reduction in stockholders’ equity, which then became negative. The subsequent periods show continued negative equity and, consequently, ROE values that are difficult to interpret in a traditional sense. The negative equity base significantly distorts the ROE calculation, making comparisons to prior periods unreliable. The final ROE value of 1,816% in December 2025 is a mathematical artifact of dividing positive net earnings by a negative equity value.

The substantial decline in stockholders’ equity is a critical factor influencing the observed ROE trends. The movement into a deficit position in the latter part of the period necessitates further investigation to understand the underlying causes and potential implications for the company’s financial health.


Return on Assets (ROA)

AbbVie Inc., ROA calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Net earnings attributable to AbbVie Inc.
Total assets
Profitability Ratio
ROA1
Benchmarks
ROA, Competitors2
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q4 2025 Calculation
ROA = 100 × (Net earnings attributable to AbbVie Inc.Q4 2025 + Net earnings attributable to AbbVie Inc.Q3 2025 + Net earnings attributable to AbbVie Inc.Q2 2025 + Net earnings attributable to AbbVie Inc.Q1 2025) ÷ Total assets
= 100 × ( + + + ) ÷ =

2 Click competitor name to see calculations.


The Return on Assets (ROA) exhibited considerable fluctuation throughout the observed period, spanning from March 31, 2022, to December 31, 2025. Initial values demonstrated a strong performance, followed by a marked decline and subsequent stabilization with some volatility.

Initial Performance (Mar 31, 2022 – Sep 30, 2022)
The ROA began at 8.71% in March 2022 and peaked at 9.49% in September 2022. This period indicates a consistently high level of profitability relative to total assets. A slight increase is observed from March to June, followed by a further increase through September.
Decline and Stabilization (Dec 31, 2022 – Mar 31, 2024)
A significant downward trend commenced in December 2022, with the ROA falling to 3.61% by December 2023. This decline suggests diminishing profitability in relation to asset utilization. The ROA experienced a modest recovery, reaching 4.03% in March 2024, but remained substantially lower than the values recorded in the earlier part of the period.
Recent Volatility (Jun 30, 2024 – Dec 31, 2025)
From June 2024 onwards, the ROA displayed increased volatility. It decreased to 3.17% in December 2024, experiencing a negative value of -22% in the same period. A subsequent increase to 3.15% was observed by December 2025, indicating some recovery, but the overall trend remains unstable. The lowest point was observed in December 2024, which is an outlier compared to the rest of the period.
Net Earnings and Total Assets Relationship
The decline in ROA generally correlates with fluctuations in net earnings attributable to the company. While total assets also decreased over certain periods, the more pronounced changes in net earnings appear to be a primary driver of the observed ROA trends. The negative net earnings in December 2024 significantly impacted the ROA for that period.

Overall, the ROA demonstrates a shift from strong initial performance to a period of decline and recent instability. Further investigation into the factors influencing net earnings and asset utilization is warranted to understand the underlying causes of these trends.